Our range of fully profiled syngeneic mouse models in a number of histotypes continues to expand as we work to provide our clients with the most advanced platform from which to launch their studies. Validation parameters at Charles River include assessment of response to known immune checkpoint inhibitors CTLA-4, PD-1, and PDL-1 to assist in proper selection for combination therapies.
In addition, in-house multiplex flow cytometry enables a comprehensive analysis of the immune system, allowing identification of various cell populations and deep interrogation of an immune response elicited from novel therapeutics. With a streamlined process for tissue dissociation, cell isolation, staining and acquisition, hundreds of systemic and tumor-infiltrating immune cells can be processed per day to give clients the benefit of reviewing data and making decisions about compounds and studies in near-real time.
Figure 1: Cells are analyzed based on viability and expression profiles; resulting data reveal effect of compounds on multiple cell types involved in immune responses.
Our expert staff have developed and validated panels of flow assays for identification and profiling of several relevant immune cells, such as CD4+ and CD8+ effector T cells, helper and regulatory T cells, myeloid-derived suppressor cells, macrophages and natural killer cells. Additionally, we routinely develop customized panels to identify specific immune cells critical to a particular program. Any of these panels, standard or custom, measured in combination with traditional biomarkers and other endpoints tailored to the program, build a complete data package to drive decision-making.
Figure 2: In this example, immune cell-specific staining and gating strategies enable us to quantify the populations of CD4+ and CD8+ T cells, regulatory T cells and myeloid-derived suppressor cells.